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Background: This study aimed the use of mesoporous silica under the naturally transformable Neisseria
meningitidis, an important pathogen implicated in the genetic horizontal transfer of DNA causing a escape of the
principal vaccination measures worldwide by the capsular switching process. This study verified the effects of
mesoporous silica under N. meningitidis transformation specifically under the capsular replacement.
Methods: we used three different mesoporous silica particles to verify their action in N. meningitis transformation
frequency.
Results: we verified the increase in the capsular gene replacement of this bacterium with the three mesoporous
silica nanoparticles.
Conclusion: the mesouporous silica particles were capable of increasing the capsule replacement frequency in N.
meningitidis.
Findings
Freshly isolated Neisseria meningitidis are naturally com-
petent and exchange genetic information with each other
by this process. They are also known as a commensal
bacterium of the human upper respiratory tract that may
occasionally provoke invasive infections such as septice-
mia and meningitis. This natural competence has been
directly correlated to pilliation of these organisms [1] as
well as a specific uptake sequence contained multifold
within the genome of these bacteria. Pilliated strains are
easily transformed by direct incubation with a plasmid
containing the uptake sequence or chromosomal DNA
[2]. The advantages of doing genetic manipulations
within these well-known strains are numerous. Develop-
ment of systems to construct specific genomic mutations
has been used to study their pathogenesis [3-5].
The use of the mutations for the study of the capsular
polysaccharide of N. meningitidis allowed the advances in
the meningococci pathogenesis understandings [6-8]. The
capsular polysaccharide is a major virulence factor and a
protective antigen. Meningococcal strains are classified
into 12 different serogroups according to their capsular
immune specificity, among wich the serogroups A, B, C, Y
and W135 are the most frequently found in invasive infec-
tions. The capsule of serogroups B, C, Y and W135 strains
is composed of either homopolymers (B and C) or hetero-
polymers (Y and W135) of sialic acid-containing polysac-
charides that are specifically linked, depending on the
serogroup [9-11]. This polymerization is mediated by the
polysialyltransferase, encoded by the siaD gene in strains
of serogroups B and C (also called synD and synE, respec-
tively) and by synG in serogroup W135. Capsule switching
after replacement of synE, in a serogroup C strain, by synG
may result from the conversion of capsule genes by trans-
formation and allelic recombination [3,12,13]. The capsule
switching from serogroup C to B N. meningitidis was
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[3,14-17]. It might explain the emergence and the clonal
expansion of strains of serogroup W135 of N. meningitidis
in the year 2000 among Hajj pilgrims who had been vacci-
nated against meningococci of serogroups A and C
[11,18]. These W135 strains belong to the same clonal
complex ET-37/ST-11 as prominent serogroup C strains
involved in outbreaks worldwide [12,19]. Hence, the emer-
gence of these W135 strains in epidemic conditions raised
the question about a possible capsule switching as an
escape mechanism to vaccine-induced immunity. Also,
these events are expected to occur continuously and can
be selected by immune response against a particular cap-
sular polysaccharide [11]. However, the interference of
immune response with transformation efficacy has not yet
been evaluated. Specific capsular antibodies are expected
to bind to the bacterial surface and hence the interference
in DNA recognition and uptake.
In addition, environmental interference on the trans-
formation process of this bacterium is also unknown.
This work aimed at the use of different mesoporous silica
SBA-15, SBA-16 and [SBA-15/P(N-iPAAm)], an organic-
inorganic hybrids systems based on mesoporous materi-
als and stimuli-responsive polymers, for the study of
these nanostructures effect on the transformation process
of meningococci, specifically their functions on capsular
switching process. Mesoporous silica materials are a fairly
new type of material that has pores in the mesoscopic
range of 2-50 nm. The characteristic features of ordered
mesoporous materials are their monodispersed and
adjustable pore size in an inert and biocompatible matrix
with an easily modified surface. The intrinsic uniform
porous structure of this class of compounds with their
large specific surface area and pore volume, associated
with surface silanol groups, makes these materials suita-
ble as an adsorbent model for studies involving surface
phenomena. The methods used in this work verified the
effect of mesoporous silica SBA-15, SBA-16 and [SBA-
15/P(N-iPAAm)] on the transformation of the serogroup
C N. meningitidis against two different donor DNA
obtained from mutants of this microorganism (M2 and
M6).
The characteristics of the strains (N. meningitidis and
Escherichia coli) used in this study are described in Table
1. N. meningitidis were grown at 37°C under 5% CO2 on
GCB agar medium (Difco) containing the supplements
described by Taha et al, [20]. When needed, culture
media were supplemented with erythromycin at 2 μg/ml
and spectomycin at 40 μg/ml. E. coli strains used for plas-
mid preparations were DH5a.
The mesoporous silica nanoparticles SBA-15, SBA-16
and [SBA-15/P(N-iPAAm)] were characterized by Sousa
et al. [21]. Both, SBA-15 and SBA-16 are composed of
SiO2 but the characteristic features of SBA-15 are the
presence of channels arranged in a two-dimensional
hexagonal structure and wheat like macroscopic mor-
phology with mean sizes in micrometer scale which con-
sist of many ropelike aggregates. On the other hand,
SBA-16 is an example of ordered mesoporous silica with
a three dimensional cubic cage structure with three
dimensional channel connectivity. Also, in SBA-16 the
arrays of the ordered and uniform pores can be
observed for which each spherical particle is a single
crystal arranged in cubic structure.
The SEM images of SBA15 evidence the presence of
elongated, 590 nm-wide vermicular shaped particles. SBA-
15 consists of many rope-like domains with average sizes
of 1.7 μm aggregated into wheat-like macrostructures,
Figure 1(a). A similar morphology is observed after the
polymerization of P(N-iPAAm) inside the SBA-15 net-
work, presenting 450 nm width (data not showed). TEM
image of SBA-15 shows a well-defined hexagonal arrange-
ment of uniform pores when the incident electron beam
was parallel to the main axis of the mesoporous (Figure
1b), and unidirectional channels, when the electron beam
was perpendicular to the channel axis (Figure 1c). The
SBA-16 particle observed from SEM exhibits rounded
shape with diameter size between 15 and 20 μmw i t ha n
“aggregated morphology”. The corresponding TEM images
of the SBA-16, Figure 2, showed well arranged cubic
mesopores what confirmed the 3D cubic pore structure.
Some mesoporous textural properties of SBA-15 and
SBA-16 were obtained by the nitrogen adsorption mea-
sure. Table 2 summarizes these properties of SBA-15 and
Table 1 Bacterial Strains used in this work
Strain Characteristics Origin (Reference)
DH5∝ Escherichia coli F-, endA1, hsdR17 c, supE44, thi-1, gir A96, relA1 [44]
pLAN45 Plasmid containing ΔNMB0065::ΩaaDA This work
pLAN13 Plasmid containning the fusion of synG::ermAM This work
C2135 Neisseria meningitidis serogroup C, BIOMERIEUX INCQS-FIOCRUZ
W135ATCC Neisseria meningitidis serogroup W135, ATCC35559 INCQS-FIOCRUZ
M2 N.meningitidis isogenic mutant ΔNMB0065:: ΩaaDA This work
M6 W135ATCC transformed with pLAN13 to generate a fusioned strain synG:ermAM This work
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from adsorption data in the relative pressure interval P/P0
= 0.045-0.25. A cross-sectional area of 0.162 nm
2 was used
for the nitrogen molecule in the BET calculations. The
total pore volume, Vp, was calculated from the amount of
N2 adsorbed at the highest P/P0 (P/P0 = 0.99). The pore
diameter, DBJH, was calculated using the adsorption
branches of the nitrogen isotherms employing the BJH
algorithm. SBA-15, SBA-16 and SBA-15/P(N-iPAAm)
have small pore diameters from 3.7 to 5.7 nm with very
narrow pore size distributions (data not shown). Total
pore volumes for SBA-15, SBA-16 and SBA-15/P(N-
iPAAm) can also be calculated to be 0.96 cm
3/g, 0.49 cm
3/
g and 0.48 cm
3/g, respectively. SBA-15 has a higher sur-
face area than the SBA-16 and SBA-15/P(N-iPAAm).
Recombinant DNA protocols as cloning plasmids,
PCR amplifications, insertion of resistance cassettes and
transformation were performed as described previously
[20,22]. The oligonucleotides used are listed in Table 3.
All the mutants obtained by homologous recombination
were checked by PCR analysis using a oligonucleotide
harboring the target gene and another harboring the
cassette. The Figures 3 and 4 describe the design of
mutants-M2 and M6, respectively, whose genomic DNA
were extracted for gene transfer in C2135 receptor
strain.
A preliminary analysis of the action of the mesoporous
silica was performed to determine the influence of this
nanostructure under Neisseria meningitidis growth. The
results did not show any influence on bacterial growth
of the presence of DNA in addition of SBa15, SBa16 or
SBA-15/P(N-iPAAm) (data not showed).
The first mutant referent to NMB0065 sequence
mutants was the strain M2, this mutant had the
NMB0065 sequence from N. meningitidis C2135 ampli-
fied using 03.12-3 and 03.12-4 oligonucleotides (Table 3).
This fragment was cloned into the pGEM-T Easy Vector
System II (Promega Corporation, Madison, WI, USA), to
generate the plasmid pLAN6. E. coli strain Z501 was
transformed with plasmid pLAN6 resulting in the plas-
mid pLAN7. The ΩaaDA cassette was inserted into the
BclI site of pLAN7 to generate plasmid pLAN45, which
was transformed into the C2135 strain to generate the
strain M2 (Figure 3).
The construction of serogroup W135 mutants with
transcriptional fusion synG:: ermAM was initiated by
amplifying the region of synG gene using the 98-30 and
03-12-5 oligonucleotides (Table 3) on DNA from the
serogroup W135atcc strain. The amplified fragment was
cloned into the pGEM-T Easy Vector System I (Pro-
m e g a ,M a d i s o n ,W I ,U S A ) ,t og e n e r a t et h ep l a s m i d
pLAN11. Another fragment was amplified using the 04-
02-2/galECK29A from synG downstream sequence,
cloned into pGEM-T Easy Vector, to generate pLAN52.
The ermAM cassette was amplified by ERAM1/ERAM3
and insered into NcoI site of pLAN52 to generate
pLAN53. The fragment amplified from pLAN53 with
the ERAM1 and galECK29A [23] was inserted into PstI
site of pLAN11 to generate pLAN13-2. This plasmid
was linearised by the enzyme SphI and transformed into
W135ATCC strain to generate the synG::ermAM fusion
strain M6, erythromycin resistant (Figure 4).
The analysis of transformation index on SBA-15/SBA-
16 nanoparticles action is performed adding of each one
in 1.10
8 colony forming units (CFU) the receptor strain
C2135 was added of 1 μgo fM 2o rM 6g e n o m i cD N A
and 30 μg of different mesoporous silica in well plates
(table 4 and Figure 5). A negative control was also per-
formed without mesoporous silica. The suspension was
Figure 1 (a) SEM image of SBA-15 which evidence the
presence of elongated, vermicular shaped particles 590 nm
wide. TEM image of SBA-15, which shows a well-defined hexagonal
arrangement of uniform pores when (b) the incident electron beam
was parallel to the main axis of the mesopores and unidirectional
channels, and (c) the electron beam was perpendicular to the
channel axis.
Figure 2 (a) SEM image of SBA-16 exhibits rounded shape with
diameter size between 15 and 20 μm and of an “aggregated
morphology”. TEM images of SBA-16 showed well ordered cubic
mesoporous which confirmed the 3D cubic pore structure, when
(b) viewed along the pore axis and (c) perpendicularly to the pore
axis.
Table 2 N2 adsorption results





SBA-16 3.7 550 0.49
SBA-15 5.7 672 0.96
SBA-15/P(N-iPAAm) 3.7 326 0.48
SBET is the specific area, DBJH is the average pore diameter and Vp is the
average pore volume.
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Oligonucleotide Sequence 5’-3 ’ Description
03.12-3 TGCGGATCCGCAGTAATTTTATCGGTTGG NMB0065 forward
03.12-4 CCCCACTACCTAAAAAATGCTGATTTG NMB0065 reverse
aadA1 TGCCGTCACGCAACTGGTCCA ΩaaDA forward
aadA2 CAACTGATCTGCGCGCGAGGC ΩaaDA reverse
98.30 GGTGAATCTTCCGAGCAGGAAA synG forward
98.31 AAAGCTGCGCGGAAGAATAGTG synG reverse
03.12-5* TCGGGATCCTTATTTTTCTTGGCCAAAAA synG reverse
04.02-1 CAATGAATCTCGCGTTGCTGTAGGTG synG forward
04.02-2 GAAAAATAATTTGGGGCTTAGG synG forward
galECK29A CTTCCATCATTTGTGCAAGGCTGC galE reverse
ERAM1 GCAAACTTAAGAGTGTGTTGATAG ermAM forward
ERAM3 AAGCTTGCCGTCTGAATGGGACCTCTTTA GCTTCTTGG ermAM reverse
*The underlined sequences in italic are the insertion of the BamHI site into original sequence
Figure 3 Schematic representation of the capsule genes of C serogroup in disrupted construction of NMB0065 gene with aaDA
cassette. The NMB0065 gene was amplified using the 03-12-3 and 03-12-4 oligonucleotides (Table 3) from C2135 strain. This fragment was
cloned into the pGEM-T Easy Vector System II (Promega Corporation, Madison, WI, USA), to generate the plasmid pLAN6. E. coli strain Z501 was
transformed with plasmid pLAN6 resulting in the plasmid pLAN7. The ΩaaDA cassette was inserted into the BclI site of pLAN7 to generate
plasmid pLAN45, which was transformed into the C2135 strain to generate the isogenic mutant strain M2.
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these conditions. The counts of total cfu were per-
formed in GCB spectinomycin or erythromycin plates in
triplicate analysis (for M2 and M6 isogenic mutants
respectively). The CFU obtained in plates containing
specific antibiotic were analyzed by PCR, searching the
presence of target gene transfer in the transforming
units (ΩaaDA cassette for the M2 DNA and synG for
M6 donor DNA).
The graphic of Figure 5 shows significant increase of
transformation frequencies using M2 and M6 donor
DNA and the mesoporous silica SBA-15, SBA-16 and
SBA-15/P(N- i P A A m ) .T h eu s eo fad i f f e r e n tD N A
donor had as aim the certification of the independence
of mesoporous silica effect on the same bacterial strain-
N. meningitidis C2135. The analysis of the PCR had
demonstrated the transfer of the gene synG from M6
donor strains to C2135 receptor strain (data not
showed).
The data analyses were made by ratio values between
the numbers of transformants CFU obtained with meso-
porous silica action by the median value of
Figure 4 Schematic representation of the capsule genes of W135 serogroup in transcriptional fusion of synG with ermAM cassette. The
synG gene responsible for the synthesis of the W135 capsule was amplified using the 98-30 and 03-12-5 oligonucleotides (Table 3) from
W135ATCC strain. The amplified fragment was cloned into the pGEM-T Easy Vector System I (Promega, Madison, WI, USA), to generate the
plasmid pLAN11. In the same conditions, another fragment was amplified using the 04.02-2/galECK29A from synG downstream sequence to
generate pLAN52. The ermAM cassette was insered into NcoI site of pLAN52 to generate pLAN53. The fragment amplified from pLAN53 with the
ERAM1 and galECK29A (Dolan Livengood [23] et al., 2003) was insered into PstI site of pLAN11 to generate pLAN13-2. This plasmid was
linearised by the enzyme SphI and transformed into W135ATCC strain to generate the synG::ermAM strain M6, erythromycin resistant.
Hollanda et al. Journal of Nanobiotechnology 2011, 9:28
http://www.jnanobiotechnology.com/content/9/1/28
Page 5 of 8transformants CFU obtained without silica treatment.
The values were analyzed by ANOVA one-way analysis
of variance (Tukey test compared each treatment to
control without mesoporous silica in transformation).
The meningococci growth was not affected by the pre-
sence of mesoporous silica (data not shown).
As showed in table 4, the significant values of P < 0.05
obtained in the ratio values between transformation
using the donors M2 and M6 mutants DNA, respec-
tively. These values are considered significant when
compared with the transformation frequency obtained
from negative control without silica action. Thus, the
actions of mesopourous silica under the meningococci
transformation increased the capacity of the C2135
strains, specially using the construction M6, directly
implicated in the capsular switching outbreaks.
Despite the exact mechanism of the capsular switching
is still under investigation, we proposed that this process
is related to the action of mesoporous silica structures in
the transformation frequencies in 1.10
8 cfu, with a signifi-
cant increase when mesoporous silica was used. The
behavior of SBA-16, regarding to transformation process
of C2135 strain with donor DNA from M2 mutant, was
different from that observed for the others. This nano-
particle showed increase of transformation frequency
more than SBA-15, and SBA-15/P(N-iPAAm) mesopor-
ous silica. Besides the differences in the textural proper-
ties showed in Table 2, a probable cause for the different
responses is the presence of singular morphological
arrangements, as they are hierarchically organized in a
special way. Moreover, it is worth noticing that the three-
dimensional interconnected pore structure of sample
SBA-16 can facilitate the occurrence of adsorption.
The important information is the chromosomal locali-
zation of the NMB0065 and synG gene. Both are gene of
bacterial chromosome and their biological characteristics
determined in Neisseria meningitidis when these genes
are recombined onto chromosomes level. Nevertheless,
N. meningitidis rarely replicate the plasmids provided
from E.coli constructions, as those performed in these
work (plasmids from pLAN series), exceptionally when in
the plasmid carrier antibiotic resistant from another spe-
cies of Neisseria as N. gonorrhoeae [24-26].
Also the practical implications of the silica action
under meningococci are very important to the workers
that usually are exposed at these nanoparticles [27-29].
The careful action of adopting the safety measures not
only the silicosis [30-33] but also for adopting safety
mesures to prevent not only silicosis but also changing
pathology and host adaptation of N. meningitidis, will be
important in places where silica nanoparticles are pre-
sent, especially in aerosols. This work is the first to cite
the relationships between the silica risks of health
caused by meningococcal capsular switching or capsular
replacement. This neglected process is described just as
an immunologically controlled phenomenon not
Table 4 Values obtained from C21 35 Transformation using the donor DNA from M2 and M6 mutants
Donor DNA (1 μg) Mean of the UCF transformants
obtained in 1.10
8 UFC
Ratio (means obtained exposed to silica/
mean of negative control)




932 ± 175,50 1,00 ± 0,11
SBa 15 + DNA M2 1696 ± 73,30 1,52 ± 0,25 (P < 0,05)
SBa 16 + DNA M2 1840 ± 423,32 1,97 ± 0,22 (P < 0,05)
SBa 15 (P(N-iPAAm) + DNA M2 1544 ± 358,10 1,38 ± 0,05 (P < 0,05)
Negative Control (without
mesoporous silica) M6
106 ± 10,00 0,92 ± 0,06
SBa 15 + DNA M6 364,33 ± 117,11 3,17 ± 0,80 0,0475 (P < 0,05)
SBa 16 + DNA M6 558,70 ± 59,56 4,50 ± 0,43 0,0008 (P < 0,05)
SBa 15 (P(N-iPAAm) + DNA M6 598,67 ± 107,56 5,20 ± 0,80 0,0058 (P < 0,05)
Figure 5 Graphic of the transformation ratio obtained with In
A: ratio of transformation of C2135 strain with donor DNA
from M2 mutant (ΔNMB0065:: ΩaaDA), In B: ratio of
transformation of C2135 strain with donor DNA from M6
mutant (synG:: ermAM), mimicking a capsular switch
replacement, significant analysis of both tests were performed
by Tukey test comparing separately each treatment SBA-15,
SBA-16 and SBA-15/P(N-iPAAm) with the control without
nanoparticles (w/o).
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sence of the nanostructures in the atmosphere.
Nevertheless, the capsular switching is described in
regions as the sub Saharan Africa [11,34-36] and Saudi
Arabia (Hajj pilgrimage) [34,37-43] in desert zones
where probably silica nanostructures are present that
facilities the capsular switching process. New experi-
ments using the animal models could confirm this
hypothesis and has been performed by the research
group for Neisseria meningitdis and other natural com-
petent bacteria as Streptococcus pneumoniae and Hae-
mophilus influenzae.
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